PO:24:063 | Interstitial lung disease in idiopathic inflammatory myopathy patients: efficacy and safety of nintedanib: Giulia Buonsante1|2|3, Giacomo De Luca1|2|3, Veronica Batani1|2, Lorenzo Dagna1|2|3, Marco Matucci-Cerinic1|2|3, Corrado Campochiaro1|2|3 | 1Unit of Immunology, Rheumatology, Allergy and Rare Diseases UNIRAR, IRCCS San Raffaele Hospital Milano, Italy; 2Inflammation, Fibrosis and aging Initiative INFLAGE, IRCCS San Raffaele Hospital Milano, Italy; 3Vita-Salute San Raffaele University, Milano, Italy. Reumatismo [Internet]. 2026 Mar. 18 [cited 2026 Aug. 17];77(s1). Available from: https://www.reumatismo.org/reuma/article/view/2350